Yang YH. Letter to the Editor: Integrating immune-related metrics with personalize first-line immunochemotherapy in human epidermal growth factor receptor 2-negative advanced gastric cancer. World J Gastrointest Oncol 2026; 18(5): 116411 [DOI: 10.4251/wjgo.v18.i5.116411]
Corresponding Author of This Article
Yu-Han Yang, Assistant Professor, West China School of Medicine, Sichuan University, No. 17 People’s South Road, Chengdu 6100041, Sichuan Province, China. yyh_1023@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Correspondence
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
May 15, 2026 (publication date) through May 14, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Yang YH. Letter to the Editor: Integrating immune-related metrics with personalize first-line immunochemotherapy in human epidermal growth factor receptor 2-negative advanced gastric cancer. World J Gastrointest Oncol 2026; 18(5): 116411 [DOI: 10.4251/wjgo.v18.i5.116411]
World J Gastrointest Oncol. May 15, 2026; 18(5): 116411 Published online May 15, 2026. doi: 10.4251/wjgo.v18.i5.116411
Letter to the Editor: Integrating immune-related metrics with personalize first-line immunochemotherapy in human epidermal growth factor receptor 2-negative advanced gastric cancer
Yu-Han Yang
Yu-Han Yang, West China School of Medicine, Sichuan University, Chengdu 6100041, Sichuan Province, China
Author contributions: Yang YH was responsible for conceptualization, writing original draft preparation, writing review and editing, read and approved the final manuscript and agreed to be accountable for all aspects of the work.
AI contribution statement: There have been no use of AI tools for the manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Corresponding author: Yu-Han Yang, Assistant Professor, West China School of Medicine, Sichuan University, No. 17 People’s South Road, Chengdu 6100041, Sichuan Province, China. yyh_1023@163.com
Received: November 11, 2025 Revised: December 22, 2025 Accepted: January 9, 2026 Published online: May 15, 2026 Processing time: 184 Days and 13 Hours
Core Tip
Core Tip: This study developed and validated a novel survival prediction model for advanced human epidermal growth factor receptor 2 negative gastric cancer patients receiving immunotherapy combined with chemotherapy. A retrospective analysis of 200 patients identified programmed death ligand 1 expression, microsatellite instability, tumor-node-metastasis stage, tumor differentiation, neutrophil-to-lymphocyte ratio, and C-reactive protein-albumin-lymphocyte index as independent prognostic factors. Based on these factors, nomogram models for progression-free survival and overall survival were constructed and validated using the concordance index and area under the curve. The results showed good discrimination ability in both the training and validation sets, indicating that the model effectively predicts patient survival outcomes and provides strong support for personalized treatment decisions.
